{"id":"cytokine-induced-killer-cell-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CIK cells are autologous or allogeneic T cells cultured with cytokines (IFN-γ, IL-2, anti-CD3) to generate a population enriched for CD8+ and NK-like T cells with enhanced cytotoxic capacity. These cells recognize tumor-associated antigens and infected cells, inducing apoptosis through perforin/granzyme and death receptor pathways. The therapy leverages both adaptive and innate immune mechanisms to target malignant cells.","oneSentence":"Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes that recognize and kill tumor cells through multiple pathways including TCR and NK receptor engagement.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:36.825Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT04836728","phase":"PHASE2","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-31","conditions":"Non-small Cell Lung Cancer Metastatic, First-line Treatment","enrollment":156},{"nctId":"NCT01868490","phase":"PHASE1, PHASE2","title":"The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Siriraj Hospital","startDate":"2009-04-17","conditions":"Cholangiocarcinoma, Neuroblastoma","enrollment":20},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT04634435","phase":"PHASE1","title":"Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2021-10-21","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT05268172","phase":"PHASE1","title":"IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites","status":"RECRUITING","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Pleural Effusion, Malignant","enrollment":40},{"nctId":"NCT03757858","phase":"PHASE1, PHASE2","title":"Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2018-03-01","conditions":"Cancer, Abdominal Cancer, Pelvic Cancer","enrollment":40},{"nctId":"NCT03393858","phase":"PHASE1, PHASE2","title":"Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2017-12-01","conditions":"Cancer, Mesothelioma, Malignant","enrollment":10},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT01884168","phase":"","title":"Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-03","conditions":"Malignant Tumor","enrollment":30},{"nctId":"NCT03190811","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-09","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT03360630","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-11-01","conditions":"Lung Cancer, Neoplasms","enrollment":60},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT00699816","phase":"PHASE3","title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-07","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT04802070","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"COMPLETED","sponsor":"Prof. Franca Fagioli","startDate":"2021-01-11","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT05676190","phase":"NA","title":"Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer","status":"RECRUITING","sponsor":"ShiCang Yu","startDate":"2023-01-09","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT03782363","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"WITHDRAWN","sponsor":"Italian Sarcoma Group","startDate":"2020-12-18","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT04476641","phase":"PHASE2","title":"A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05-06","conditions":"Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer","enrollment":686},{"nctId":"NCT03987867","phase":"PHASE1","title":"Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer, First-line Treatment","enrollment":30},{"nctId":"NCT03987698","phase":"PHASE2","title":"Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":90},{"nctId":"NCT03983759","phase":"PHASE2","title":"Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-06-20","conditions":"Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy","enrollment":40},{"nctId":"NCT02585908","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of γδ T Cell Against Gastric Cancer","status":"UNKNOWN","sponsor":"Beijing Doing Biomedical Co., Ltd.","startDate":"2019-12","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT01631357","phase":"PHASE2, PHASE3","title":"Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT01691664","phase":"NA","title":"Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Cancer","enrollment":40},{"nctId":"NCT02425748","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2017-06-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03736330","phase":"PHASE2","title":"A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-09-08","conditions":"Renal Cancer Metastatic","enrollment":24},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT01894373","phase":"PHASE1, PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-06","conditions":"Psoriasis, Adoptive Immunotherapy","enrollment":10},{"nctId":"NCT01781520","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-06-01","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT03220984","phase":"PHASE2","title":"The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2017-03-16","conditions":"Metastatic Colorectal Cancer","enrollment":28},{"nctId":"NCT03158480","phase":"NA","title":"Safety and Efficacy of Immune Therapy for Condyloma","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2017-06-25","conditions":"Condylomata Acuminata","enrollment":80},{"nctId":"NCT00394381","phase":"PHASE1, PHASE2","title":"Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, High Grade","enrollment":17},{"nctId":"NCT00815321","phase":"PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2008-12","conditions":"Chronic Myeloid Leukemia","enrollment":11},{"nctId":"NCT00460694","phase":"PHASE1, PHASE2","title":"Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia","enrollment":24},{"nctId":"NCT03047525","phase":"PHASE1, PHASE2","title":"Study of DC-CTL Combined With CIK for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Xiaoyi Huang","startDate":"2017-02-20","conditions":"Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT02886897","phase":"PHASE1, PHASE2","title":"A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-07","conditions":"Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer","enrollment":50},{"nctId":"NCT02539017","phase":"PHASE2","title":"The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2015-11","conditions":"Triple Negative Breast Neoplasms","enrollment":""},{"nctId":"NCT02418481","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02425735","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT02491697","phase":"PHASE2","title":"Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-02","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02498756","phase":"PHASE2","title":"Cytokine-induced Killer Study for Patients With Stage II Melanoma","status":"NOT_YET_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-08","conditions":"Melanoma","enrollment":300},{"nctId":"NCT02280278","phase":"PHASE3","title":"Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":"Stage III Colon Cancer","enrollment":550},{"nctId":"NCT01478074","phase":"PHASE1","title":"ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Altor BioScience","startDate":"2011-11","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT01871480","phase":"PHASE2","title":"CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Kunming Medical University","startDate":"2013-05","conditions":"Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT01929499","phase":"PHASE2","title":"Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer","status":"UNKNOWN","sponsor":"Yanjuan Zhu","startDate":"2013-09","conditions":"Colonic Neoplasms","enrollment":210},{"nctId":"NCT01902875","phase":"","title":"Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2013-06","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT00697671","phase":"PHASE1","title":"Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-03","conditions":"Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia","enrollment":48},{"nctId":"NCT00185757","phase":"PHASE1","title":"Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation","status":"UNKNOWN","sponsor":"Robert Negrin","startDate":"2004-06","conditions":"Multiple Myeloma, Blood and Marrow Transplant (BMT)","enrollment":20},{"nctId":"NCT01481259","phase":"PHASE2, PHASE3","title":"Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2010-01","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT01592422","phase":"PHASE2","title":"Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2012-07","conditions":"Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT01240005","phase":"PHASE1, PHASE2","title":"Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2011-01","conditions":"Renal Cell Carcinoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cytokine-induced killer cell immunotherapy","genericName":"Cytokine-induced killer cell immunotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes that recognize and kill tumor cells through multiple pathways including TCR and NK receptor engagement. Used for Hepatocellular carcinoma, Gastric cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}